# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Anthony Vendetti downgrades Zivo Bioscience (OTC:ZIVO) from Buy to Hold.
Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of the...
Zivo Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and ...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by J...
On Thursday, 369 companies hit new 52-week lows.